Dr John Wesley Mcconnell, MD | |
100 W Market St Ste 2, Louisville, KY 40202-1332 | |
(502) 587-8000 | |
(502) 583-8001 |
Full Name | Dr John Wesley Mcconnell |
---|---|
Gender | Male |
Speciality | Pulmonary Disease |
Experience | 42 Years |
Location | 100 W Market St Ste 2, Louisville, Kentucky |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1902831761 | NPI | - | NPPES |
64227267 | Medicaid | KY |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RP1001X | Internal Medicine - Pulmonary Disease | 22726 (Kentucky) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Norton Hospitals, Inc | Louisville, KY | Hospital |
Clark Memorial Hospital | Jeffersonville, IN | Hospital |
Hardin Memorial Hospital | Elizabethtown, KY | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Community Medical Associates Inc | 7012811284 | 1098 |
News Archive
NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform.
Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.
Researchers say on a daily basis around 275 Australians develop type 2 diabetes and worldwide, every 30 seconds a person somewhere has a lower limb amputated because of diabetic foot disease.
‘Cybersickness' might sound right out of a sci-fi novel, but it's an illness impacting people across industries today. UNSW Sydney researchers are trying to understand what causes this sickness – and how to prevent it.
› Verified 4 days ago
Entity Name | University Of Kentucky |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1770771974 PECOS PAC ID: 3072425289 Enrollment ID: O20031105000072 |
News Archive
NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform.
Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.
Researchers say on a daily basis around 275 Australians develop type 2 diabetes and worldwide, every 30 seconds a person somewhere has a lower limb amputated because of diabetic foot disease.
‘Cybersickness' might sound right out of a sci-fi novel, but it's an illness impacting people across industries today. UNSW Sydney researchers are trying to understand what causes this sickness – and how to prevent it.
› Verified 4 days ago
Entity Name | Community Medical Associates Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1588614994 PECOS PAC ID: 7012811284 Enrollment ID: O20031120000656 |
News Archive
NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform.
Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.
Researchers say on a daily basis around 275 Australians develop type 2 diabetes and worldwide, every 30 seconds a person somewhere has a lower limb amputated because of diabetic foot disease.
‘Cybersickness' might sound right out of a sci-fi novel, but it's an illness impacting people across industries today. UNSW Sydney researchers are trying to understand what causes this sickness – and how to prevent it.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Dr John Wesley Mcconnell, MD Po Box 776351, Chicago, IL 60677-6351 Ph: (502) 588-9490 | Dr John Wesley Mcconnell, MD 100 W Market St Ste 2, Louisville, KY 40202-1332 Ph: (502) 587-8000 |
News Archive
NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform.
Patients with inflammatory rheumatic diseases (IRD) treated with anti-tumour necrosis factor medications (anti-TNFs) have a 75% greater risk of developing herpes zoster, or shingles, than patients treated with traditional disease modifying anti-rheumatic drugs (DMARDs), according to a meta-analysis presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism.
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for hyperoxaluria, a debilitating condition that, if untreated, leads to kidney damage and end-stage renal disease.
Researchers say on a daily basis around 275 Australians develop type 2 diabetes and worldwide, every 30 seconds a person somewhere has a lower limb amputated because of diabetic foot disease.
‘Cybersickness' might sound right out of a sci-fi novel, but it's an illness impacting people across industries today. UNSW Sydney researchers are trying to understand what causes this sickness – and how to prevent it.
› Verified 4 days ago
Cindy J Code, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 3950 Kresge Way, Suite 303, Louisville, KY 40207 Phone: 502-896-1880 Fax: 502-896-1887 | |
Dr. Uchenna Loretta Ozor, M.D Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 200 E Chestnut St Bldg Suite303, Louisville, KY 40202 Phone: 502-629-5552 Fax: 502-629-3132 | |
Mohamed Hegazi, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 529 S Jackson St, Louisville, KY 40202 Phone: 502-562-4270 | |
Dr. Michael Patrick Krease, D.O. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1169 Eastern Pkwy Ste G58, Louisville, KY 40217 Phone: 502-452-9567 | |
Dr. Ramsey Nasri Nassar, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6400 Dutchmans Pkwy, Ste 250, Louisville, KY 40205 Phone: 502-587-9660 Fax: 502-540-5615 | |
Jeanne M Thompson, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3 Audubon Plaza Dr, Ll2, Louisville, KY 40217 Phone: 502-636-8095 Fax: 502-636-8097 | |
Terrence P Donohue, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3101 Poplar Level Rd Ste 101, Louisville, KY 40213 Phone: 502-636-7444 Fax: 502-636-7112 |